SHROOM4 and lung carcinoma: Our analysis demonstrated a notable downregulation of SHROOM4 mRNA and protein expression, along with its high diagnosis capability in lung cancer, especially pronounced in LUSC, Additionally, higher levels of SHROOM4 were linked to worse clinical outcomes in lung cancer, characterized by reduced survival and more advanced disease stages.